AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
171.14
-4.13 (-2.36%)
Jul 18, 2024, 4:01 PM EDT - Market closed

Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.

Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.

It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology.

The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.
AbbVie logo
Country United States
Industry Drug Manufacturers - General
Sector Healthcare
Employees 50,000
CEO Robert A. Michael

Contact Details

Address:
1 North Waukegan Road
North Chicago, Illinois 60064
United States
Phone (847) 932-7900
Website abbvie.com

Stock Details

Ticker Symbol ABBV
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001551152
CUSIP Number 00287Y109
ISIN Number US00287Y1091
Employer ID 32-0375147
SIC Code 2834

Key Executives

Name Position
Richard A. Gonzalez Chairman and Chief Executive Officer
Robert A. Michael President and Chief Operating Officer
Scott T. Reents Executive Vice President and Chief Financial Officer
Dr. Azita Saleki-Gerhardt Ph.D. Executive Vice President and Chief Operating Officer
Jeffrey Ryan Stewart Executive Vice President and Chief Commercial Officer
Dr. Thomas J. Hudson M.D. Senior Vice President and Chief Scientific Officer of Global Research
Elizabeth Shea Senior Vice President of Investor Relations
Perry C. Siatis Executive Vice President, General Counsel and Secretary
Sanjay Narayan Senior Vice President, Chief Ethics, Compliance Officer and Allergan Aesthetic Legal
Timothy J. Richmond Executive Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Jul 17, 2024 144 Filing
Jul 3, 2024 8-K Current Report
Jun 27, 2024 11-K Annual report of employee stock purchase, savings and similar plans
Jun 3, 2024 25-NSE Filing
May 31, 2024 SD Form - SD
May 17, 2024 25-NSE Filing
May 8, 2024 8-K/A [Amend] Current report
May 3, 2024 10-Q Quarterly Report
Apr 26, 2024 8-K Current Report
Apr 3, 2024 8-K Current Report